Lakeside Holding Is Now Quanome Technologies On Nasdaq, Six Months After A $1.00 Sale Of Its Freight Arm

by Nikolai Petrov · August 17, 2026

Technology Reporter, Frontier Tech Wire

The quantum sector picked up a new Nasdaq ticker this month, and it did not come from a laboratory. On August 5, a company datelined Itasca, Illinois said its common stock had begun trading on the Nasdaq Capital Market as Quanome Technologies, Inc. under the symbol QNME, and described itself as building "technologies, applications, and partnerships at the intersection of quantum computing, artificial intelligence, advanced simulation and intelligent systems." The same SEC registrant, then named Lakeside Holding Limited, had asked its shareholders roughly six months earlier to approve the sale of its logistics subsidiary for one dollar to a buyer that would assume all of that subsidiary's liabilities.

The announcement, distributed by GlobeNewswire, sets out the application areas the company intends to pursue: quantum and AI-enabled decision systems, molecular and materials simulation, and pharmaceutical and healthcare uses, with energy systems, industrial engineering, financial systems, cybersecurity and post-quantum cryptography named as longer-term areas. Chief Executive Yang Li is quoted at length. "Quantum technology is not simply about performing existing calculations faster," he said, "it has the potential to help solve problems that conventional computing cannot address effectively - this includes discovering new medicines, designing advanced materials to improve energy systems, securing digital infrastructure and optimizing complex industries. Quanome is now focused on identifying technologies, partnerships and business opportunities that grow our participation in emerging quantum-related fields."

Read in full, the release names no acquisition, no research partner, no licensed technology and no dollar figure, and the chief executive's own wording matches that: he places the company at the stage of identifying technologies, partnerships and business opportunities rather than announcing any. The corresponding Form 8-K, filed the same day, likewise carries no financial terms in the version reproduced by StockTitan; its substantive content is the name change, the ticker change and the strategic description. A company is entitled to state an intention before it has assets to describe, and this one states it plainly.

The listing facts are as stated: the shares are quoted on the Nasdaq Capital Market under QNME, and the bid-price rule the company has been cited under, Nasdaq Listing Rule 5550(a)(2), is a Capital Market rule. Both StockTitan and stockanalysis.com still classify the company under integrated freight and logistics, and stockanalysis.com still describes a cross-border supply chain business operating in the United States, China and South Korea. The two providers disagree on the most recent price. StockTitan showed a close of $0.4625 for Friday, August 14, timestamped that evening; stockanalysis.com's page was still showing a close of $0.5168 from Tuesday, August 11, alongside a market capitalization of about $17.8 million on 34.43 million shares outstanding. Nothing has traded since Friday's close. On either provider's figure, the company's market value is under $20 million.

The February record is where the story sits. In a preliminary revised proxy statement filed on EDGAR ahead of a special meeting, the board asked holders to approve the sale of American Bear Logistics Corp., an Illinois corporation. The document states that "the Company will sell all of its right, title and interest in ABL to the Purchaser for a purchase price of $1.00," and that "the Purchaser will assume all liabilities of ABL and its subsidiaries, of any nature whatsoever, whether arising before, on or after the closing date, whether absolute, contingent or otherwise, and whether or not disclosed to the Purchaser." The proxy describes the buyer only as an unaffiliated third party purchaser, does not name it, and discloses no relationship between the buyer and the company's officers or directors.

The board's stated rationale, in the same document, is that "divesting ABL will allow the Company to focus its resources and management attention on its core operations and strategic priorities," and that by transferring the liabilities "the Company will eliminate its exposure to ABL's ongoing obligations and contingent liabilities." The proxy notes that ABL "has experienced operating challenges and currently has negative net asset values." A nominal price paired with a full assumption of liabilities is an ordinary structure for disposing of a unit that owes more than it owns, and the proxy presents it as one.

The same proxy carried the capital-structure work. It asked holders to increase the authorized common stock to 2,000,000,000 shares, to authorize 1,000,000,000 shares of blank check preferred stock with a par value of $0.0001, and to ease certain shareholder voting thresholds. It also sought ratification of a December 2025 private placement of 5,600,000 shares at $0.14 a share, for aggregate gross proceeds of $784,000. The record date was January 5, 2026, with 34,427,559 shares outstanding. TipRanks, reporting the vote, said holders representing 93.12% of outstanding shares were represented at the February 12 meeting and that the proposals were approved, including the ABL sale.

The quarterly report filed on May 19 shows the business that remained. The figures that follow are as rendered in StockTitan's presentation of that 10-Q rather than read from the filing text: revenue from continuing operations of $5,108,387 for the nine months ended March 31, 2026, a nine-month net loss of $2,798,489, and cash of $1,300,306 against $4,814,872 at the June 30, 2025 fiscal year end. On liquidity, StockTitan quotes the filing as saying: "These factors, among others, raise the substantial doubt regarding the Company's ability to continue as a going concern." It records the disposal of ABL Chicago effective February 12, 2026 — the date of the shareholder meeting — as discontinued operations, with a gain of $2,556,315, and describes the continuing business as pharmaceutical distribution.

A separate summary of the same filing, published by TradingView, corroborates the shape of that quarter from a different hand: revenue of $1.33 million against $497,000 a year earlier, net income of $142,000 after a $1.07 million loss in the prior-year quarter, pharmaceutical sales up roughly 614% year to date, active customers up from eight to 14, and the same February 12 disposal of ABL Chicago reclassified to discontinued operations. That summary does not state whether the quarter's net income includes the gain booked on the disposal, and this article does not assume either way.

The listing clock is the other document set, and it also settles dates that secondary sources report inconsistently. StockTitan's index of the company's filings shows an 8-K on August 3 recording the adoption of the new name and ticker, the shelf amendment on August 4 filed under the new name, and trading under QNME beginning August 5, the date of both the press release and a second 8-K. Earlier in the year, Investing.com, summarizing the company's disclosure, reported a Nasdaq notice dated January 7, 2026 for failure to hold a $1.00 closing bid price under Listing Rule 5550(a)(2), opening a 180-day period that ran to July 7. The index records an 8-K on July 10 reporting that Nasdaq granted a second 180-day period running to January 4, 2027.

A $120 million shelf registration on Form S-3 followed on July 8, and the August 4 filing was an amendment to that same shelf rather than a second one — the index shows one $120 million registration, amended once, with the amendment flagging PRC regulatory and Holding Foreign Companies Accountable Act audit risks alongside the extended bid-price deadline. The July shelf's cover priced the stock at $0.4198 as of July 7.

The risk arithmetic is on the face of the documents rather than in anyone's model. Two billion authorized common shares sit above 34,427,559 outstanding. One billion shares of blank check preferred are authorized with the terms — dividends, conversion, voting — left to the board. A $120 million shelf sits above a market capitalization under $20 million, and no offering under it has been announced; the shelf as summarized by StockTitan states no ceiling of its own. Under the SEC's published guidance on smaller companies' use of Form S-3, an issuer whose public float is below $75 million may not sell more than one-third of that float in primary offerings on the form over any 12 calendar months, a limit measured on shares held by non-affiliates rather than on the registered amount. The going-concern language stands in the last filed quarterly report, and the bid-price deadline is January 4, 2027.

There is a straightforward test ahead. The company's fiscal year ended June 30, 2026, so its next annual report will be the first audited document to describe the business under the Quanome name, and the first place a quantum asset, license or contract would have to appear if one exists. Reviewed on August 17, StockTitan's index of the company's SEC filings shows nothing filed after the August 5 Form 8-K and no acquisition agreement or technology purchase at any point since the rebrand. Until something is filed, the public record behind the new name is the strategy the company has described and the pharmaceutical distribution business it already reports.